AU2020101855A4 - Citrus and flammulina velutipes tabletting candy and preparation method thereof - Google Patents
Citrus and flammulina velutipes tabletting candy and preparation method thereof Download PDFInfo
- Publication number
- AU2020101855A4 AU2020101855A4 AU2020101855A AU2020101855A AU2020101855A4 AU 2020101855 A4 AU2020101855 A4 AU 2020101855A4 AU 2020101855 A AU2020101855 A AU 2020101855A AU 2020101855 A AU2020101855 A AU 2020101855A AU 2020101855 A4 AU2020101855 A4 AU 2020101855A4
- Authority
- AU
- Australia
- Prior art keywords
- parts
- citrus
- flammulina velutipes
- powder
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 240000006499 Flammulina velutipes Species 0.000 title claims abstract description 42
- 235000016640 Flammulina velutipes Nutrition 0.000 title claims abstract description 42
- 235000020971 citrus fruits Nutrition 0.000 title claims abstract description 41
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 36
- 241000207199 Citrus Species 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000843 powder Substances 0.000 claims abstract description 35
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 14
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 14
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 14
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 12
- 229940069765 bean extract Drugs 0.000 claims abstract description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 11
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 10
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 8
- 229940054810 white kidney bean extract Drugs 0.000 claims abstract description 7
- 239000004375 Dextrin Substances 0.000 claims description 16
- 229920001353 Dextrin Polymers 0.000 claims description 16
- 235000019425 dextrin Nutrition 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 235000019864 coconut oil Nutrition 0.000 claims description 7
- 239000003240 coconut oil Substances 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013618 yogurt Nutrition 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 4
- 235000019408 sucralose Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 235000021243 milk fat Nutrition 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229940080237 sodium caseinate Drugs 0.000 claims description 3
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 3
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 3
- 235000019197 fats Nutrition 0.000 abstract description 39
- 230000000694 effects Effects 0.000 abstract description 19
- 230000007423 decrease Effects 0.000 abstract description 14
- 238000010521 absorption reaction Methods 0.000 abstract description 13
- 238000009825 accumulation Methods 0.000 abstract description 8
- 229930006000 Sucrose Natural products 0.000 abstract description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 7
- 239000005720 sucrose Substances 0.000 abstract description 7
- 229920002472 Starch Polymers 0.000 abstract description 5
- 235000019577 caloric intake Nutrition 0.000 abstract description 5
- 238000002485 combustion reaction Methods 0.000 abstract description 5
- 239000008107 starch Substances 0.000 abstract description 5
- 235000019698 starch Nutrition 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 210000001789 adipocyte Anatomy 0.000 description 12
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000000229 preadipocyte Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 2
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- -1 amino oligosaccharide Chemical class 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 239000008358 core component Substances 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WQSACWZKKZPCHN-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N)CC(C)C)CCC1 WQSACWZKKZPCHN-UHFFFAOYSA-N 0.000 description 1
- PLXKZKLXYHLWHR-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,3-dimethylbutan-1-amine Chemical compound C=1C=C(Cl)C=CC=1C1(C(CC(C)C)NC)CCC1 PLXKZKLXYHLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 1
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 244000045930 Phaseolus coccineus Species 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical class O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000008590 ayocote Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229950009125 cynarine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/46—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing dairy products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Austracy
The present invention discloses a citrus and Flammulina velutipes tabletting
candy. The candy includes the following raw materials in parts by weight: 5-20 parts
of white kidney bean extract, 5-30 parts of dried skim milk, 3-15 parts of
L-arabinose, 3-10 parts of vegetable fat powder, 1-10 parts of Flammulina velutipes
powder, 0.1-20 parts of chitosan oligosaccharide, 0.1-20 parts of citrus fruit powder,
0.1-20 parts of green coffee bean extract, 0.1-5 parts of powdered conjugated
linoleic acid glycerides and 0.1-10 parts of epigallocatechin gallate. The candy can
promote fat combustion, lower fat accumulation, block starch and sucrose absorption
and decrease energy intake. Moreover, the citrus and Flammulina velutipes tabletting
candy provided by the present invention is excellent in taste and convenient to carry
and has no toxic or side effect.
1
Description
Austracy
The present invention discloses a citrus and Flammulina velutipes tabletting candy. The candy includes the following raw materials in parts by weight: 5-20 parts of white kidney bean extract, 5-30 parts of dried skim milk, 3-15 parts of L-arabinose, 3-10 parts of vegetable fat powder, 1-10 parts of Flammulina velutipes powder, 0.1-20 parts of chitosan oligosaccharide, 0.1-20 parts of citrus fruit powder, 0.1-20 parts of green coffee bean extract, 0.1-5 parts of powdered conjugated linoleic acid glycerides and 0.1-10 parts of epigallocatechin gallate. The candy can promote fat combustion, lower fat accumulation, block starch and sucrose absorption and decrease energy intake. Moreover, the citrus and Flammulinavelutipes tabletting candy provided by the present invention is excellent in taste and convenient to carry and has no toxic or side effect.
Description
Technical Field
The present invention relates to the technical field of food, and food processing, and particularly relates to a citrus and Flammulina velutipes tabletting candy and a preparation method thereof.
Background
Obesity is a chronic metabolic disease caused by many factors. It has the characteristics as follows: the percent of body fat accounting for weight is abnormally increased due to the increase of volume and number of adipose cells in the body, and certain local parts have excessive fat deposition. The obesity mainly includes primary obesity and secondary obesity. The primary obesity is mainly related to genetic factor, high fat diet, excessive sitting, long-term game playing, lack of exercise and other harmful manners. The secondary obesity is mainly related to internal secretion and metabolic diseases. The obesity may be prevented and treated by means of low fat and low sugar, reasonable diet with balanced and comprehensive nutrition, and prevention of intake of too much sugar and fat, acceleration of fat consumption and decrease of fat accumulation. Some supplementary fat-reduced food is also needed when necessary. However, most of the existing fat-reduced products are brewing preparations, are inconvenient to carry and eat and poor in taste, and easily produce side effects. Therefore, the problem that urgently needs to be solved by those skilled in the art is how to provide a citrus and Flammulina velutipes tabletting candy that is good in taste and convenient to carry and has no side effect and a preparation method thereof.
Description
Summary In view of this, the present invention provides a citrus and Flammulina velutipes tabletting candy capable of promoting fat combustion, lowering fat accumulation, blocking starch and sucrose absorption and decreasing energy intake. Moreover, the citrus and Flammulina velutipes tabletting candy provided by the present invention is excellent in taste and convenient to carry and has no toxic or side effect. In order to realize the above purpose, the present invention adopts the following technical solutions: The citrus and Flammulina velutipes tabletting candy includes the following raw materials in parts by weight: 5-20 parts of white kidney bean extract, 5-30 parts of dried skim milk, 3-15 parts of L-arabinose, 3-10 parts of vegetable fat powder, 1-10 parts of Flammulina velutipes powder, 0.1-20 parts of chitosan oligosaccharide, 0.1-20 parts of citrus fruit powder, 0.1-20 parts of green coffee bean extract, 0.1-5 parts of powdered conjugated linoleic acid glycerides and 0.1-10 parts of epigallocatechin gallate. The white kidney bean has a scientific name of Phaseolus multiflorus and another name of kidney bean. The white kidney bean is dry and gentle in property and flavor, can achieve the effects of warming middle and descending qi, tonifying kidney and reinforcing vital energy, enhancing gastrointestinal functions and tranquilizing and allaying excitement, and is an excellent diet therapy food. The a-amylase inhibitor (a-A) in the white kidney bean can completely block an interaction channel between a substrate and active sites of a-amylase, thereby completely inhibiting the activity of the a-amylase in saliva and pancreas and hindering hydrolysis and digestion of carbohydrates in food. In the present invention, the added white kidney bean extract can obviously reduce weight, reduce fat and narrow the waistline, without influencing muscular tissues.
Description
The chitosan oligosaccharide is also known as oligochitosan or amino oligosaccharide, is an oligoglucosamine having a polymerization degree of 2-10 linked by P-1,4 glycoside bonds, and is the unique cationic basic amino oligosaccharide with positive charges in nature. The chitosan oligosaccharide is an animal cellulose, is also known as an "alkaline saccharide", and has the characteristics of water-retaining property, expansibility, adsorptivity and digestive absorption difficulty. The chitosan oligosaccharide can adsorb fatty acids and bile acid and block fat absorption. The chitosan oligosaccharide can improve fat accumulation in the body and remove fatty liver, may serve as prebiotics of intestinal beneficial bacteria to improve intestinal microecology, and can activate vascular walls and red blood cells, lower cholesterol and treat diabetes. The citrus fruit powder comes from 100% natural citruses (e.g., Red orange, Grapefruit, Orange and guarana), contains more than 60% of polyphenols, achieves effects of PDEs, and inhibition of inactivation of phosphodiesterase to cAMP (cyclic adenosine monophosphate). The cAMP has major effects of activating triglyceride lipase, and promoting triglyceride in adipose cells to decompose into glycerol and free fatty acids to enter a tricarboxylic acid cycle to produce energy. The cAMP can further inhibit cathecol-methyl transferase activity in the body, facilitate release of epinephrine and norepinephrine, stimulate a P-3 receptor, facilitate the consumption of the fat and the increase of metabolism, and has no side effect on kidney, liver and cardiac vessel functions. Flammulina velutipes is a bioactive substance prepared from edible Flammulina velutipes fruiting bodies by virtue of hot water extraction and alkaline treatment, and includes main components such as plant chitosan, p-glucan, complex carbohydrates and fatty acid mixtures. The Flammulina velutipes extract promotes decomposition of fat accumulated in the body and inhibits intestinal absorption of the fat to decrease the fat in the body. The green coffee bean extract is enriched in 45-75% of chlorogenic acid and more than or equal to 15% of 5-dicaffeoylquinic acid (neochlorogenic acid). The major component chlorogenic acid in the green coffee bean extract has the effect of
Description
inhibiting adipose cell maturation and differentiation factor (PPAR-y), inhibits preadipocyte differentiation, inhibits free fatty acids from synthesizing triglyceride and avoids the massive increase of adipose cells in the body and accumulation of the fat (triglyceride) in the adipose cells. Moreover, caffeine in green coffee can promote metabolism of the body, increase the cAMP concentration in the cells by inhibiting activity of cAMP lytic enzymes, activate the activity of lipolytic enzyme, promote adipolysis, and decrease the volume of an adipose cell layer and the quantity of the adipose cells. The powdered conjugated linoleic acid glyceride comes from 100% food-grade safflower oil, is extracted by utilizing an advanced conjugation reaction, and has conjugated linoleic acid content of more than or equal to 40%. It can inhibit synthesis of LPL (lipoprotein lipase), decrease synthesis of triglyceride from fatty acids entering the adipose cells, inhibit proliferation and differentiation of preadipocyte, and slow down maturation of the adipose cells. Moreover, the powdered conjugated linoleic acid glyceride can also inhibit synthesis of fatty acids from acetyl coenzyme A and malonyl CoA under catalysis of fatty synthetase FAS, decrease fat decomposition in the body, increase related enzymes of fatty acid oxidation and decomposition such as acyl CoA synthetase, phospholipid hydrolase and acyl coenzyme oxidase, and promote oxidation and combustion of the fatty acid. The epigallocatechin gallate (EGCG) is a catechin with the highest content in green tea, is also the most effective bioactive component in the green tea, and has the effects of resisting oxidation and reducing weight. Antioxidant activity of the EGCG is more than 100 times of vitamin C and 25 times of vitamin E. The EGCG promotes expressions of acyl coA oxidase (ACO) and fatty acyl-CoA dehydrogenase (MCAD)mRNA and f-oxidation activities, and promotes fat oxidation. The EGCG can reduce expression of preadipocyte VEGF, PPAR-y, C/EBPaD and the expression of the mRNA, thereby inhibiting differentiation and proliferation of the preadipocyte and the adipose cells, achieving the effect of weight reduction, promoting adipolysis of mature adipose cells and decreasing the
Description
quantity and volume of mature cells. Moreover, EGCG monomers have inhibitory effects on a-amylase, a-glucosidase and pancreatic lipase. The dried skim milk contains proteins, is also enriched in butter fat, lactose and mineral substances, and has high content of calcium, phosphorus, iron, zinc, copper, manganese and molybdenum. The L-arabinose is prepared by enzymatic isomerization of D-xylose with a uridine diphosphate derivative, and has a physiological effect of selectively affecting sucrase in small intestines so as to inhibit sucrose absorption. Researches prove that, the L-arabinose can inhibit sucrose absorption by 60-70%, and can decrease a blood glucose level by about 50%. Preferably, the above citrus and Flammulina velutipes tabletting candy further includes 20-50 parts of sorbitol, 10-30 parts of xylitol, 5-20 parts of yoghurt powder, 10-30 parts of resistant dextrin, 0.1-5 parts of lactic acid, 0.1-3 parts of p-carotene, 0.3-1 part of magnesium stearate, 0.01-0.1 part of sucralose and 0.1-1 part of edible essence. Preferably, in the above citrus and Flammulina velutipes tabletting candy, the resistant dextrin is Fibersol-2 resistant dextrin. The Fibersol-2 resistant dextrin is a water-soluble dietary fiber derived from natural corn starch, and has the characteristics of high dietary fiber, high water solubility, high stability, high moisture resistance, low sweetness, low viscosity, low water activity and low calorie. The resistant dextrin is hydrolyzed in the small intestines by about 10-15% and fermented in the large intestine by about 75%. About 10-15% of the residual resistant dextrin is excreted from faces. Moreover, in the large intestine, the resistant dextrin is not suddenly or excessively fermented, and thus may not cause gastrointestinal discomfort, stomachache and diarrhea. Preferably, in the above citrus and Flammulina velutipes tabletting candy, the vegetable fat powder includes medium chain triglyceride. Preferably, in the above citrus and Flammulina velutipes tabletting candy, the vegetable fat powder further includes anhydrous milk fat, refined coconut oil, resistant dextrin, fatty acid monoglyceride/diglyceride, and silica.
Description
Preferably, in the above citrus and Flammulina velutipes tabletting candy, the vegetable fat powder further includes resistant dextrin, sodium caseinate, fatty acid monoglyceride/diglyceride and sodium hexametaphosphate. Medium chain fat molecules in the coconut oil are smaller than long-chain fat molecules of other food, so the coconut oil is easily digested and absorbed by the human body and is not stored and transformed by liver. Moreover, the coconut oil contains no cholesterol. Diet coconut oil is digested without a human pancreatic digestive enzyme system, and applies a very low pressure to enzyme and hormone systems of the body. The medium chain triglyceride (MCT) is medium chain fat, and is a triglyceride composed of fatty acids of 6-12 carbon atoms, wherein main components of the triglyceride are octanoic acid (C8:0) and capric acid (C10:0). The MCT is small in molecule, excellent in water solubility, capable of being easily hydrolyzed from fat, and fast in absorption. The MCT is transferred into liver to metabolize via a portal vein after absorption, and is difficult to be taken by adipose tissues and accumulated in the body. One of the mechanisms for preventing obesity by the medium chain fatty acids is taste and satiety. Food intake and energy intake are decreased for animals; oxidation and energy supply are faster; a higher thermic effect of food is achieved; and energy consumption is increased. The citrus and Flammulina velutipes tabletting candy in the present invention is prepared by dry direct tabletting without a granulation (wet granule or dry granule) step; the technological process is simple, energy-saving and time-saving; stability of functional components may be maintained to the full extent; and a dissolution rate of the functional components is increased. Moreover, influences of heating and water are avoided, and stability of functional raw materials is protected. Through the above technical solutions, compared with the prior art, the present invention provides the citrus and Flammulina velutipes tabletting candy and the preparation method thereof. The present invention has advantages as follows:
Description
(1) For the primary core components in the present invention, the citrus fruit powder promotes the fat combustion; the conjugated linoleic acid decreases the fat ratio and increases the metabolism; the epigallocatechin gallate decreases the fatty synthetase and promotes fat metabolism; the medium chain triglyceride accelerates basic fat metabolism; the Flammulina velutipes powder is coated with oil and inhibits fat absorption and decomposition; the green coffee bean extract decomposes and reduces the fat; the chitosan oligosaccharide decreases adipose cell transformation and decreases fat accumulation; and septuple fat burning raw materials are scientifically mixed, so that fat burning is more effective, and fat accumulation is decreased. (2) For the secondary core components in the present invention, the white kidney bean contains the a-amylase inhibiting substance and can inhibit the activity of the amylase and decrease hydrolysis and digestive absorption of starch; and the L-arabinose has the effect of selectively affecting sucrase in the small intestines so as to inhibit sucrose absorption. In the present invention, by virtue of the effect of regulating in-vivo enzymes, the effects of promoting fat burning and metabolism and decreasing fat decomposition are achieved, and the digestive system is not damaged. (3) The citrus and Flammulina velutipes tabletting candy in the present invention can effectively block starch and sucrose absorption and decrease energy intake. (4) The citrus and Flammulina velutipes tabletting candy in the present invention comprises pure food components, is safe and harmless to safely eat, is convenient to pack and carry, and can be eaten anytime and anywhere.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and fully described below. Apparently, the described embodiments are
'7
Description
merely part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by those ordinary skilled in the art without contributing creative labor will belong to the protection scope of the present invention. Embodiment 1 Embodiment 1 provides a citrus and Flammulina velutipes tabletting candy, including the following raw materials in parts by weight: 5 parts of white kidney bean extract, 5 parts of dried skim milk, 3 parts of L-arabinose, 3 parts of medium chain triglyceride, 1 part of Flammulina velutipes powder, 0.1 part of chitosan oligosaccharide, 0.1 part of citrus fruit powder, 0.1 part of green coffee bean extract, 0.1 part of powdered conjugated linoleic acid glycerides and 0.1 part of epigallocatechin gallate. Embodiment 2 Embodiment 2 provides a citrus and Flammulina velutipes tabletting candy, including the following raw materials in parts by weight: 20 parts of white kidney bean extract, 30 parts of dried skim milk, 15 parts of L-arabinose, 10 parts of vegetable fat powder, 10 parts of Flammulina velutipes powder, 20 parts of chitosan oligosaccharide, 20 parts of citrus fruit powder, 20 parts of green coffee bean extract, 5 parts of powdered conjugated linoleic acid glycerides, 10 parts of epigallocatechin gallate, 50 parts of sorbitol, 30 parts of xylitol, 20 parts of yoghurt powder, 30 parts of resistant dextrin, 5 parts of lactic acid, 3 parts of p-carotene, 1 part of magnesium stearate, 0.1 part of sucralose and 1 part of edible essence. The vegetable fat powder is composed of medium chain triglyceride, anhydrous milk fat, refined coconut oil, resistant dextrin, fatty acid monoglyceride/diglyceride, and silica. Embodiment 3 Embodiment 3 provides a citrus and Flammulina velutipes tabletting candy, including the following raw materials in parts by weight: 10 parts of white kidney
Description
bean extract, 20 parts of dried skim milk, 10 parts of L-arabinose, 5 parts of vegetable fat powder, 5 parts of Flammulina velutipes powder, 10 parts of chitosan oligosaccharide, 10 parts of citrus fruit powder, 10 parts of green coffee bean extract, 3 parts of powdered conjugated linoleic acid glycerides, 5 parts of epigallocatechin gallate, 20 parts of sorbitol, 10 parts of xylitol, 5 parts of yoghurt powder, 10 parts of resistant dextrin, 0.1 part of lactic acid, 0.1 part of p-carotene, 0.3 part of magnesium stearate, 0.01 part of sucralose and 0.1 part of edible essence. The vegetable fat powder is composed of medium chain triglyceride, resistant dextrin, sodium caseinate, fatty acid monoglyceride/diglyceride and sodium hexametaphosphate. Nutritional ingredients in the citrus and Flammulina velutipes tabletting candy in embodiments 1-3 are detected, and results are shown in Table 1: Table 1 Nutritional ingredient table Energy Protein Fat Carbohydrate Sodium Tabletting candy per 1790±10kJ 4.1±0.3g 9.2±0.5g 81.2±2g 180±10mg 100g NRV% 21±0.5 7±0.2 15±0.3 27±1 9±0.5
In the present invention, the citrus and Flammulina velutipes tabletting candy in embodiments 1-3 is subjected to physical and chemical detection of multiple pharmaceutical ingredients. Detection results are s shown in Table 2: Table 2 Physical and chemical detection results
Detection item Unit Detection method Detection result Detection limit
Orlistat pg/kg BJS 201701 HPLC-MS/MS Negative 5.00
Ephedrine pg/g BJS201710 LC-MS/MS Negative 3.2 Fenfluramine pg/g BJS201710 LC-MS/MS Negative 0.90
Furosemide pg/g BJS201710 LC-MS/MS Negative 9.4
N-monodesmethyl sibutramine pg/g BJS201710 LC-MS/MS Negative 0.98
N,N-bis-desmethylsibutramine pg/g BJS201710 LC-MS/MS Negative 0.35
Phenolphthalein pg/g BJS201710 LC-MS/MS Negative 0.40
Sibutramine pg/g BJS201710 LC-MS/MS Negative 0.35 Lovastatin pg/g BJS201710 LC-MS/MS Negative 0.35
Description Mevastatin pg/g BJS201710 LC-MS/MS Negative 0.49
Simvastatin pg/g BJS201710 LC-MS/MS Negative 0.36
The citrus and Flammulina velutipes tabletting candy in the present invention has yogurt flavor, is chewable, and is mainly used for facilitating shaping and fat burning. Each tablet of candy has 2 g; 2 tablets are eaten each time, for 1-3 times per day; and the tablet is unsuitable to be eaten by infants, pregnant women and lactating women. Various embodiments of the present invention are described in a progressive manner. Each embodiment focuses on the difference from other embodiments, while same or similar parts of all embodiments can be referred to each other. For a solution disclosed by the embodiments, because the solution corresponds to a method disclosed by the embodiments, the solution is simply described. Refer to the description of the method part for the related part. The above description of the disclosed embodiments enables those skilled in the art to realize or use the present invention. Many modifications to these embodiments will be apparent to those skilled in the art. The general principle defined herein can be realized in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to these embodiments shown herein, but will conform to the widest scope consistent with the principle and novel features disclosed herein.
1 )
Claims (5)
1. A citrus and Flammulina velutipes tabletting candy, comprising the following raw materials in parts by weight: 5-20 parts of white kidney bean extract, -30 parts of dried skim milk, 3-15 parts of L-arabinose, 3-10 parts of vegetable fat powder, 1-10 parts of Flammulina velutipes powder, 0.1-20 parts of chitosan oligosaccharide, 0.1-20 parts of citrus fruit powder, 0.1-20 parts of green coffee bean extract, 0.1-5 parts of powdered conjugated linoleic acid glycerides and 0.1-10 parts of epigallocatechin gallate.
2. The citrus and Flammulina velutipes tabletting candy according to claim 1, further comprising 20-50 parts of sorbitol, 10-30 parts of xylitol, 5-20 parts of yoghurt powder, 10-30 parts of resistant dextrin, 0.1-5 parts of lactic acid, 0.1-3 parts of p-carotene, 0.3-1 part of magnesium stearate, 0.01-0.1 part of sucralose and 0.1-1 part of edible essence.
3. The citrus and Flammulina velutipes tabletting candy according to claim 1 or 2, wherein the vegetable fat powder comprises medium chain triglyceride.
4. The citrus and Flammulina velutipes tabletting candy according to claim 3, wherein the vegetable fat powder further comprises anhydrous milk fat, refined coconut oil, resistant dextrin, fatty acid monoglyceride/diglyceride, and silica.
5. The citrus and Flammulina velutipes tabletting candy according to claim 3, wherein the vegetable fat powder further comprises resistant dextrin, sodium caseinate, fatty acid monoglyceride/diglyceride and sodium hexametaphosphate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020101855A AU2020101855A4 (en) | 2020-08-17 | 2020-08-17 | Citrus and flammulina velutipes tabletting candy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020101855A AU2020101855A4 (en) | 2020-08-17 | 2020-08-17 | Citrus and flammulina velutipes tabletting candy and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020101855A4 true AU2020101855A4 (en) | 2020-09-24 |
Family
ID=72513349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020101855A Ceased AU2020101855A4 (en) | 2020-08-17 | 2020-08-17 | Citrus and flammulina velutipes tabletting candy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2020101855A4 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113951363A (en) * | 2021-10-09 | 2022-01-21 | 深圳市竣亿大健康科技有限公司 | Sea-buckthorn and ginseng tablet candy and preparation method thereof |
| CN113973965A (en) * | 2021-10-29 | 2022-01-28 | 上海圣岳生物科技有限公司 | Pressed candy containing theanine compound for relaxing mood and preparation method thereof |
-
2020
- 2020-08-17 AU AU2020101855A patent/AU2020101855A4/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113951363A (en) * | 2021-10-09 | 2022-01-21 | 深圳市竣亿大健康科技有限公司 | Sea-buckthorn and ginseng tablet candy and preparation method thereof |
| CN113973965A (en) * | 2021-10-29 | 2022-01-28 | 上海圣岳生物科技有限公司 | Pressed candy containing theanine compound for relaxing mood and preparation method thereof |
| CN113973965B (en) * | 2021-10-29 | 2023-10-13 | 上海圣岳生物科技有限公司 | Pressed candy containing theanine compound for relaxing mood of human and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104824548B (en) | Matrimony vine compound health ferment and preparation method thereof | |
| Gibson et al. | Nutrition intervention strategies to combat zinc deficiency in developing countries | |
| US20030004215A1 (en) | Dietetic preparation and method for inhibiting intestinal carbohydrate absorption | |
| CN106798252B (en) | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus | |
| WO2005023021A1 (en) | Diet food | |
| AU2020101855A4 (en) | Citrus and flammulina velutipes tabletting candy and preparation method thereof | |
| CN102366093A (en) | Composite slimming health food | |
| CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
| JPH11187843A (en) | Food and beverage composition for improving obesity and food and beverage containing the same | |
| CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
| CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
| CN104839695A (en) | Inflammatory bowel disease non-total nutrient formula food | |
| CN109222101A (en) | Composition and health food with effect of weight reducing | |
| KR20240011214A (en) | Composition for treating or preventing metabolic disease | |
| CN113349377A (en) | Slimming probiotic soft capsule and preparation method thereof | |
| CN101755878B (en) | Preparation method of weight-reducing cake containing balsam pear, hawthorn and cassia seeds | |
| KR100681532B1 (en) | Preparation method of soybean fermented food using rhizopus oligosporus | |
| JP2010100663A (en) | Enzyme inhibitor containing fermentation product of allium cepa l | |
| JP2005097222A (en) | Fermented product of allium cepa l. | |
| CN112189839A (en) | Composition for assisting in reducing blood fat and application thereof | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| CN112704717A (en) | Stomach-invigorating medicinal and edible composition for assisting treatment of advanced digestive tract tumor | |
| US20040202732A1 (en) | Composition to promote weight loss | |
| KR20200043555A (en) | Supplement food composition for diet | |
| CN114391653A (en) | Sports nutrition tablet for losing weight and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |